Katryna A Gouin1, Stephen Creasy2, Mary Beckerson2, Martha Wdowicki2, Lauri A Hicks3, Jennifer N Lind4, Andrew I Geller4, Daniel S Budnitz4, Sarah Kabbani3. 1. Chenega Corporation, contractor on assignment to the National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. PharMerica, a BrightSpring Health Services company, Louisville, Kentucky, USA. 3. Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 4. CDC COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Trends in prescribing for nursing home (NH) residents, which may have been influenced by the coronavirus disease 2019 (COVID-19) pandemic, have not been characterized. METHODS: Long-term care pharmacy data from 1944 US NHs were used to evaluate trends in prescribing of antibiotics and drugs that were investigated for COVID-19 treatment, including hydroxychloroquine, famotidine, and dexamethasone. To account for seasonal variability in antibiotic prescribing and decreased NH occupancy during the pandemic, monthly prevalence of residents with a prescription dispensed per 1000 residents serviced was calculated from January to October and compared as relative percent change from 2019 to 2020. RESULTS: In April 2020, prescribing was significantly higher in NHs for drugs investigated for COVID-19 treatment than 2019; including hydroxychloroquine (+563%, 95% confidence interval [CI]: 5.87, 7.48) and azithromycin (+150%, 95% CI: 2.37, 2.63). Ceftriaxone prescribing also increased (+43%, 95% CI: 1.34, 1.54). Prescribing of dexamethasone was 36% lower in April (95% CI: .55, .73) and 303% higher in July (95% CI: 3.66, 4.45). Although azithromycin and ceftriaxone prescribing increased, total antibiotic prescribing among residents was lower from May (-5%, 95% CI: .94, .97) through October (-4%, 95% CI: .94, .97) in 2020 compared to 2019. CONCLUSIONS: During the pandemic, large numbers of residents were prescribed drugs investigated for COVID-19 treatment, and an increase in prescribing of antibiotics commonly used for respiratory infections was observed. Prescribing of these drugs may increase the risk of adverse events, without providing clear benefits. Surveillance of NH prescribing practices is critical to evaluate concordance with guideline-recommended therapy and improve resident safety. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: Trends in prescribing for nursing home (NH) residents, which may have been influenced by the coronavirus disease 2019 (COVID-19) pandemic, have not been characterized. METHODS: Long-term care pharmacy data from 1944 US NHs were used to evaluate trends in prescribing of antibiotics and drugs that were investigated for COVID-19 treatment, including hydroxychloroquine, famotidine, and dexamethasone. To account for seasonal variability in antibiotic prescribing and decreased NH occupancy during the pandemic, monthly prevalence of residents with a prescription dispensed per 1000 residents serviced was calculated from January to October and compared as relative percent change from 2019 to 2020. RESULTS: In April 2020, prescribing was significantly higher in NHs for drugs investigated for COVID-19 treatment than 2019; including hydroxychloroquine (+563%, 95% confidence interval [CI]: 5.87, 7.48) and azithromycin (+150%, 95% CI: 2.37, 2.63). Ceftriaxone prescribing also increased (+43%, 95% CI: 1.34, 1.54). Prescribing of dexamethasone was 36% lower in April (95% CI: .55, .73) and 303% higher in July (95% CI: 3.66, 4.45). Although azithromycin and ceftriaxone prescribing increased, total antibiotic prescribing among residents was lower from May (-5%, 95% CI: .94, .97) through October (-4%, 95% CI: .94, .97) in 2020 compared to 2019. CONCLUSIONS: During the pandemic, large numbers of residents were prescribed drugs investigated for COVID-19 treatment, and an increase in prescribing of antibiotics commonly used for respiratory infections was observed. Prescribing of these drugs may increase the risk of adverse events, without providing clear benefits. Surveillance of NH prescribing practices is critical to evaluate concordance with guideline-recommended therapy and improve resident safety. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Entities:
Keywords:
COVID-19; adverse drug events; antibiotic stewardship; nursing home
Authors: Amie Taggart Blaszczyk; Katherine Sandlin; Sumeen Mirza; Lilibeth Hernandez; Hiba Bader; Ronald G Hall Journal: J Am Med Dir Assoc Date: 2022-04-06 Impact factor: 7.802
Authors: Ying Zhao; Jingru Zhang; Kai Zheng; Sydney Thai; Ross J Simpson; Alan C Kinlaw; Yang Xu; Jingkai Wei; Xiangli Cui; John B Buse; Til Stürmer; Tiansheng Wang Journal: Drugs Real World Outcomes Date: 2022-04-06
Authors: Nick Daneman; Samantha Lee; Heming Bai; Chaim M Bell; Susan E Bronskill; Michael A Campitelli; Gail Dobell; Longdi Fu; Gary Garber; Noah Ivers; Matthew Kumar; Jonathan M C Lam; Bradley Langford; Celia Laur; Andrew M Morris; Cara L Mulhall; Ruxandra Pinto; Farah E Saxena; Kevin L Schwartz; Kevin A Brown Journal: Open Forum Infect Dis Date: 2022-03-02 Impact factor: 3.835
Authors: Manon R Haverkate; Derek R Macfadden; Nick Daneman; Jenine Leal; Michael Otterstatter; Roshanak Mahdavi; Adam G D'Souza; Elissa Rennert-May; Michael Silverman; Kevin L Schwartz; Andrew M Morris; Ariana Saatchi; David M Patrick; Fawziah Marra Journal: Antibiotics (Basel) Date: 2022-07-26